==Apnimed (APMD) began trading on the Nasdaq on Fri 31 Jul 26

Sector: Pharmaceutical industry
Employees 65
Founded 201
Website apnimed.com
Apnimed opened at $22 after pricing IPO at $16/share 

• Apnimed (APMD) is off to a successful public-market debut, with its upsized 12.0 mln share IPO pricing at $16 -- the top of its $14--$16 range -- before opening at $22 for a 38% gain, signaling strong investor demand for the late-stage sleep-medicine developer.
• The biopharmaceutical company is developing oral therapies for sleep-related breathing disorders, led by Oxnimbi, also known as AD109, a once-nightly combination drug designed to improve upper-airway muscle activity and prevent airway collapse in patients with obstructive sleep apnea.
• APMD's primary end market is the large OSA population, where current treatment is dominated by devices such as CPAP, giving a convenient oral therapy the potential to expand diagnosis, treatment adoption, and patient compliance if approved.
• The company submitted an NDA for Oxnimbi in April 2026 following positive Phase 3 trials, and the FDA accepted the application for review in July, making regulatory approval and commercialization the central near-term catalysts for the story.
• For the three months ended March 31, 2026, APMD reported $84.8 mln of related-party revenue, up sharply from $3.1 mln a year earlier, while income from operations swung to $68.0 mln from a $27.1 mln loss.
• That financial improvement should be viewed cautiously, however, because the revenue was tied primarily to licensing, know-how, and research-service arrangements with its SASS joint venture rather than recurring commercial product sales, meaning the IPO's longer-term success will ultimately depend on Oxnimbi's approval, launch execution, reimbursement, and physician and patient adoption.

==Silvercrest Asset Management (SAMG)

Silvercrest Asset Management Group Inc. completed its initial public offering on June 27, 2013, trading on the NASDAQ under the ticker symbol SAMG.

Founded in 2002, the New York-based wealth management firm focuses on ultra-high-net-worth individuals, families, and institutional investors.

IPO and Offering Details

Date: June 27, 2013 (effective June 26, 2013)
Exchange / Ticker: NASDAQ: SAMG
Shares Offered: ~4.8 million shares
Price Range: $12 to $14 per share
Capital Raised: ~$62 million
Lead Underwriters: Sandler O’Neill + Partners and Raymond James

Initial Delay: Silvercrest initially filed for a $55 million IPO in September 2012, but formally withdrew it in November 2012 citing unfavorable market valuations.

==Attovia Therapeutics Inc. has filed for an IPO

Attovia Therapeutics Inc. is seeking to raise up to $212.5 million in a U.S. initial public offering by offering 12.5 million shares priced at $15 to $17 each. The San Carlos, California-based biotech firm plans to list on the Nasdaq under the ticker symbol ATTO. 

Attovia to take on Sanofi and Regeneron’s Dupixent

Galderma won FDA approval for an IL-31 drug, Nemluvio, in 2024 and doubled its peak sales forecast to more than $4 billion this year. The drug, which Galderma licensed from Roche’s Chugai in 2016, fights with products including Dupixent for the atopic dermatitis and prurigo nodularis markets.

IPO Details & Terms

Shares offered: 12.5 million common shares
Price range: $15 to $17 per share
Target raise: Up to $212.5 million (or roughly $244.4 million if underwriters exercise options)
Exchange / Ticker: Nasdaq Global Market under ATTO
Joint Bookrunners: Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital.

 Company Focus & Pipeline

Focus: Early-stage biopharmaceutical developer targeting immune-mediated inflammatory diseases. 
Platform: Uses a proprietary "ATTOBODY" platform in-licensed from Alamar Biosciences. 
Lead Candidate: ATTO-1310, an IL-31 inhibitor designed as a potential competitor to established treatments like Dupixent and Nemluvio for high-itch atopic dermatitis and chronic pruritus. 
Financial Position: Pre-revenue clinical-stage company reporting a net loss of $18.7 million for the first quarter of 2026. Proceeds from the IPO will fund upcoming Phase 2 clinical trials and pipeline expansion.